Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129948 | 0.89 | KMT2A (0.77) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL6580244 | 0.86 | NPC1 (0.64) | KMT2APOLBNPC1RAB9AALOX15 | |
| SCHEMBL6577799 | 0.85 | ALOX15 (0.57) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL6581728 | 0.85 | ALOX15 (0.57) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL7553405 | 0.84 | KMT2A (0.61) | KMT2APKMNPC1RAB9AALOX15 | |
| SCHEMBL10527844 | 0.83 | HSD17B10 (0.54) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL11793228 | 0.83 | KMT2A (0.73) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL8278418 | 0.83 | NPC1 (0.71) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL8980367 | 0.83 | KMT2A (0.60) | KMT2APKMPOLBNPC1RAB9A | |
| SCHEMBL10242069 | 0.82 | KMT2A (0.71) | KMT2APKMPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903227-B2 | Synthesis of 2-acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-0716088-B1 | PROCESS FOR PRODUCING 2-(TETRAZOL-5-YL)-4-OXO-4H-BENZOPYRANS | SUMITOMO CHEMICAL CO (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2001092250-A2 | SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-5597929-A | Production process of 2-(tetrazol-5-yl)-4-oxo-4H-benzopyran | SUMITOMO CHEMICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0716088-A1 | PROCESS FOR PRODUCING 2-(TETRAZOL-5-YL)-4-OXO-4H-BENZOPYRANS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | PLA2G7, PAFAH1B2, PAFAH1B3 | KMT2A 1048/4885PKM 2840/4885POLB 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.